Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients

• Published in: Scientific reports Vol. 14; no. 1; pp. 27491 - 11
• Main Authors: Dai, Jhih-Wei, Lin, Yuan, Li, Xiu-Wei, Tseng, Chin-Ju, Tsai, Ming-Lung, Yang, Ning-I, Hung, Ming-Jui, Chen, Tien-Hsing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.11.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/163; 692/308; 692/4019; Aged; Antidiabetics; Asian People; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular outcomes; Cerebral infarction; Creatinine; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Dialysis; Dulaglutide; Female; Glomerular Filtration Rate; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Glucagon-Like Peptides - therapeutic use; Health risks; Humanities and Social Sciences; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - therapeutic use; Ischemia; Kidneys; Liraglutide; Liraglutide - adverse effects; Liraglutide - therapeutic use; Male; Middle Aged; multidisciplinary; Myocardial infarction; Patients; Recombinant Fusion Proteins - therapeutic use; Renal outcomes; Retrospective Studies; Science; Science (multidisciplinary); Treatment Outcome; Cardiovascular outcomes; Renal outcomes; Dulaglutide; Liraglutide

Given the limited head-to-head comparison of cardiovascular and renal outcomes between liraglutide and dulaglutide, our study aimed to investigate the clinical outcomes between dulaglutide and liraglutide in a real-world setting. In this new-user design, comparative and retrospective cohort study, p...